Maturo Stephen, Hartnick Christopher J
EPI, Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, 243 Charles St, Boston, MA 02114-3914, USA.
Arch Otolaryngol Head Neck Surg. 2010 Jun;136(6):561-5. doi: 10.1001/archoto.2010.81.
To describe the initial pediatric experience with intralesional bevacizumab (Avastin) treatment for children with severe, recurrent respiratory papilloma (RRP).
Retrospective medical chart review.
Tertiary care multidisciplinary aerodigestive center.
Three children, aged 3 to 6 years, with severe RRP requiring more than 4 operative interventions in 1 year whose parents (or legal guardians) consented to adjuvant treatment with intralesional bevacizumab.
All 3 children were treated as follows: surgical debridement with a microdebrider, pulsed potassium titanyl phosphate laser treatments, and adjuvant intralesional injections with bevacizumab (1.25 mg total).
Time interval between operative interventions, Derkay severity scale for RRP, and pediatric voice-related quality of life (PVRQOL) scores.
All 3 children demonstrated increased time between operative interventions. Two children had a substantial decrease in their Derkay score and improved PVRQOL scores. One child, although time between operative interventions improved, did not have any change in Derkay score and required further adjuvant therapy.
Injectable bevacizumab appears to show some efficacy in prolonging the time between treatments and therefore reducing the number of treatments per year in children with severe RRP. However, before any meaningful conclusions can be drawn, further studies must be conducted in the form of head-to-head trials looking specifically at the issues of time between treatment intervals, efficacy of one adjunct over another, vocal outcomes, and whether several adjunctive treatments confer advantage over 1 treatment. In-depth and careful informed consent is mandatory for these studies so that parents are aware of the risks and benefits (known and unknown) before such individualized decisions are made.
描述病灶内注射贝伐单抗(阿瓦斯汀)治疗儿童重度复发性呼吸道乳头状瘤(RRP)的初步儿科经验。
回顾性病历审查。
三级医疗多学科气消化道中心。
3名3至6岁的儿童,患有重度RRP,1年内需要进行超过4次手术干预,其父母(或法定监护人)同意接受病灶内注射贝伐单抗的辅助治疗。
所有3名儿童均接受如下治疗:使用微型清创器进行手术清创、脉冲磷酸钛氧钾激光治疗,以及病灶内注射贝伐单抗(总量1.25毫克)。
手术干预之间的时间间隔、RRP的德凯严重程度量表,以及儿童语音相关生活质量(PVRQOL)评分。
所有3名儿童手术干预之间的时间间隔均延长。2名儿童的德凯评分大幅降低,PVRQOL评分有所改善。1名儿童虽然手术干预之间的时间间隔有所改善,但德凯评分没有变化,需要进一步的辅助治疗。
注射用贝伐单抗似乎在延长重度RRP患儿的治疗间隔时间方面显示出一定疗效,从而减少每年的治疗次数。然而,在得出任何有意义的结论之前,必须以头对头试验的形式进行进一步研究,具体关注治疗间隔时间、一种辅助治疗相对于另一种辅助治疗的疗效、嗓音结果,以及几种辅助治疗是否比单一治疗更具优势等问题。对于这些研究,必须进行深入且谨慎的知情同意,以便父母在做出此类个性化决定之前了解风险和益处(已知和未知)。